We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Regeneron Pharmaceuticals Inc (REGN) Common Stock USD0.001

Sell:$746.41 Buy:$747.00 Change: $2.74 (0.37%)
NASDAQ:0.18%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$746.41
Buy:$747.00
Change: $2.74 (0.37%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$746.41
Buy:$747.00
Change: $2.74 (0.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

Contact details

Address:
777 Old Saw Mill River Road
TARRYTOWN
10591
United States
Telephone:
+1 (781) 3705000
Website:
https://www.regeneron.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
REGN
ISIN:
US75886F1075
Market cap:
$81.69 billion
Shares in issue:
109.89 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Leonard Schleifer
    Co-Chairman of the Board, President, Chief Executive Officer, Founder
  • George Yancopoulos
    Co-Chairman of the Board, President, Chief Scientific Officer
  • Christopher Fenimore
    Chief Financial Officer, Senior Vice President - Finance
  • Joseph LaRosa
    Executive Vice President, General Counsel, Secretary
  • Daniel Van Plew
    Executive Vice President, General Manager - Industrial Operations and Product Supply
  • Marion McCourt
    Executive Vice President - Commercial
  • Andrew Murphy
    Executive Vice President - Research
  • Neil Stahl
    Executive Vice President - Research and Development
  • Jason Pitofsky
    Vice President, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.